Mechanism of action of phosphodiesterase type 5 inhibition in metabolic syndrome-associated prostate alterations: An experimental study in the rabbit

Prostate

Volumn 73, Issue 4, 2013, Pages 428-441

  Morelli, Annamaria ^a   Comeglio, Paolo ^a   Filippi, Sandra ^a   Sarchielli, Erica ^a   Vignozzi, Linda ^a   Maneschi, Elena ^a   Cellai, Ilaria ^a   Gacci, Mauro ^a   Lenzi, Andrea ^b   Vannelli, Gabriella B ^a   Maggi, Mario ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

BPH LUTS pathogenesis; fibrosis; hypogonadism; hypoxia; inflammation; tadalafil

Indexed keywords

CD45 ANTIGEN; MESSENGER RNA; PHOSPHODIESTERASE V; PHOSPHODIESTERASE V INHIBITOR; TADALAFIL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD PRESSURE REGULATION; CELL ACTIVATION; CONTROLLED STUDY; CYSTITIS; DRUG EFFICACY; DRUG MECHANISM; DRUG SENSITIVITY; ENZYME INHIBITION; ESTRADIOL BLOOD LEVEL; EXPERIMENTAL STUDY; FIBROSIS; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; HISTOPATHOLOGY; HYPOGONADISM; IMMUNOHISTOCHEMISTRY; INFLAMMATION; INTRAABDOMINAL FAT; LIPID DIET; LOWER URINARY TRACT SYMPTOM; LYMPHOCYTIC INFILTRATION; MALE; METABOLIC SYNDROME X; MYOFIBROBLAST; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; PROSTATITIS; PROTEIN EXPRESSION; RABBIT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TESTOSTERONE BLOOD LEVEL; TISSUE OXYGENATION;

ANIMALS; CYCLIC NUCLEOTIDE PHOSPHODIESTERASES, TYPE 5; DIET, HIGH-FAT; DISEASE MODELS, ANIMAL; MALE; METABOLIC SYNDROME X; PHOSPHODIESTERASE 5 INHIBITORS; PROSTATE; PROSTATIC HYPERPLASIA; RABBITS; UP-REGULATION;

EID: 84872195744     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.22584     Document Type: Article

References (36)

1. Després JP, Lemieux I,. Abdominal obesity and metabolic syndrome. Nature 2006; 14: 881-887. (Pubitemid 46024995)
2. Corona G, Mannucci E, Forti G, Maggi M,. Hypogonadism, ED, metabolic syndrome and obesity: A pathological link supporting cardiovascular diseases. Int J Androl 2009; 32: 587-598.
3. Mongiu AK, McVary KT,. Lower urinary tract symptoms, benign prostatic hyperplasia, and obesity. Curr Urol Rep 2009; 10: 247-253.
4. Moul S, McVary KT,. Lower urinary tract symptoms, obesity and the metabolic syndrome. Curr Opin Urol 2010; 20: 7-12.
5. Gorbachinsky I, Akpinar H, Assimos DG,. Metabolic syndrome and urologic diseases. Rev Urol 2010; 12: 157-180.
6. Parsons JK,. Lifestyle factors, benign prostatic hyperplasia, and lower urinary tract symptoms. Curr Opin Urol 2011; 21: 1-4.
7. De Nunzio C, Aronson W, Freedland SJ, Giovannucci E, Parsons JK,. The correlation between metabolic syndrome and prostatic diseases. Eur Urol 2012; 61: 560-570.
8. Fibbi B, Penna G, Morelli A, Adorini L, Maggi M,. Chronic inflammation in the pathogenesis of benign prostatic hyperplasia. Int J Androl 2010; 33: 475-488.
9. Gacci M, Corona G, Salvi M, Vignozzi L, McVary KT, Kaplan SA, Roehrborn CG, Serni S, Mirone V, Carini M, Maggi M,. A systematic review and meta-analysis on the use of phosphodiesterase 5 inhibitors alone or in combination with α-blockers for lower urinary tract symptoms due to benign prostatic hyperplasia. Eur Urol 2012; 61: 994-1003.
10. Filippi S, Vignozzi L, Morelli A, Chavalmane AK, Sarchielli E, Fibbi B, Saad F, Sandner P, Ruggiano P, Vannelli GB, Mannucci E, Maggi M,. Testosterone partially ameliorates metabolic profile and erectile responsiveness to PDE5 inhibitors in an animal model of male metabolic syndrome. J Sex Med 2009; 6: 3274-3288.
11. Mallidis C, Czerwiec A, Filippi S, O'Neill J, Maggi M, McClure N,. Spermatogenic and sperm quality differences in an experimental model of metabolic syndrome and hypogonadal hypogonadism. Reproduction 2011; 142: 63-71.
12. Vignozzi L, Morelli A, Filippi S, Comeglio P, Chavalmane AK, Marchetta M, Toce M, Yehiely-Cohen R, Vannelli GB, Adorini L, Maggi M,. Farnesoid X receptor activation improves erectile function in animal models of metabolic syndrome and diabetes. J Sex Med 2011; 8: 57-77.
13. Morelli A, Vignozzi L, Maggi M, Adorini L,. Farnesoid X receptor activation improves erectile dysfunction in models of metabolic syndrome and diabetes. Biochim Biophys Acta 2011; 1812: 859-866.
14. Vignozzi L, Morelli A, Sarchielli E, Comeglio P, Filippi S, Cellai I, Maneschi E, Serni S, Gacci M, Carini M, Piccinni MP, Saad F, Adorini L, Vannelli GB, Maggi M,. Testosterone protects from metabolic syndrome-associated prostate inflammation: An experimental study in rabbit. J Endocrinol 2012; 212: 71-84.
15. Morelli A, Comeglio P, Filippi S, Sarchielli E, Cellai I, Vignozzi L, Yehiely-Cohen R, Maneschi E, Gacci M, Carini M, Adorini L, Vannelli GB, Maggi M,. Testosterone and farnesoid X receptor agonist INT-747 counteract high fat diet-induced bladder alterations in a rabbit model of metabolic syndrome. J Steroid Biochem Mol Biol 2012; 132: 80-92.
16. Filippi S, Luconi M, Granchi S, Vignozzi L, Bettuzzi S, Tozzi P, Ledda F, Forti G, Maggi M,. Estrogens but not androgens regulate expression and functional activity of oxytocin receptor in rabbit epididymis. Endocrinology 2002; 143: 4271-4280. (Pubitemid 35239558)
17. D'Amati G, di Gioia CR, Bologna M, Giordano D, Giorgi M, Dolci S, Jannini EA,. Type 5 phosphodiesterase expression in the human vagina. Urology 2002; 60: 191-195. (Pubitemid 34722984)
18. De Lean A, Munson PJ, Rodbard D,. Simultaneous analysis of families of sigmoidal curves: Application to biomass, radioligand assay, and physiological dose response curves. Am J Physiol 1976; 235: E97-E102. (Pubitemid 9159876)
19. Vignozzi L, Cellai I, Santi R, Lombardelli L, Morelli A, Comeglio P, Filippi S, Logiodice F, Carini M, Nesi G, Gacci M, Piccinni MP, Adorini L, Maggi M,. Antiinflammatory effect of androgen receptor activation in human benign prostatic hyperplasia cells. J Endocrinol 2012; 214: 31-43.
20. Zhao C, Kim SH, Lee SW, Jeon JH, Kang KK, Choi SB, Park JK,. Activity of phosphodiesterase type 5 inhibitors in patients with lower urinary tract symptoms due to benign prostatic hyperplasia. Br J Urol Int 2011; 107: 1943-1947.
21. Filippi S, Morelli A, Sandner P, Fibbi B, Mancina R, Marini M, Gacci M, Vignozzi L, Vannelli GB, Carini M, Forti G, Maggi M,. 30. Characterization and functional role of androgen-dependent PDE5 activity in the bladder. Endocrinology 2007; 148: 1019-1029.
22. Fibbi B, Morelli A, Vignozzi L, Filippi S, Chavalmane A, De Vita G, Marini M, Gacci M, Vannelli GB, Sandner P, Maggi M,. Characterization of phosphodiesterase type 5 expression and functional activity in the human male lower urinary tract. J Sex Med 2010; 7: 59-69.
23. Morelli A, Filippi S, Comeglio P, Sarchielli E, Chavalmane AK, Vignozzi L, Fibbi B, Silvestrini E, Sandner P, Gacci M, Carini M, Vannelli GB, Maggi M,. Acute vardenafil administration improves bladder oxygenation in spontaneously hypertensive rats. J Sex Med 2010; 7: 107-120.
24. Morelli A, Sarchielli E, Comeglio P, Filippi S, Mancina R, Gacci M, Vignozzi L, Carini M, Vannelli GB, Maggi M,. Phosphodiesterase type 5 expression in human and rat lower urinary tract tissues and the effect of tadalafil on prostate gland oxygenation in spontaneously hypertensive rats. J Sex Med 2011; 8: 2746-2760.
25. McVary KT, Rademaker A, Lloyd GL, Gann P,. Autonomic nervous system overactivity in men with lower urinary tract symptoms secondary to benign prostatic hyperplasia. J Urol 2005; 174: 1327-1333. (Pubitemid 41318722)
26. Behr-Roussel D, Oger S, Caisey S, Sandner P, Bernabé J, Alexandre L, Giuliano F,. Vardenafil decreases bladder afferent nerve activity in unanesthetized, decerebrate, spinal cord-injured rats. Eur Urol 2011; 59: 272-279.
27. Morelli A, Filippi S, Sandner P, Fibbi B, Chavalmane AK, Silvestrini E, Sarchielli E, Vignozzi L, Gacci M, Carini M, Vannelli GB, Maggi M,. Vardenafil modulates bladder contractility through cGMP-mediated inhibition of RhoA/Rho kinase signaling pathway in spontaneously hypertensive rats. J Sex Med 2009; 6: 1594-1608.
28. Zenzmaier C, Sampson N, Pernkopf D, Plas E, Untergasser G, Berger P,. Attenuated proliferation and trans-differentiation of prostatic stromal cells indicate suitability of phosphodiesterase type 5 inhibitors for prevention and treatment of benign prostatic hyperplasia. Endocrinology 2010; 151: 3975-3984.
29. Bianchi-Frias D, Vakar-Lopez F, Coleman IM, Plymate SR, Reed MJ, Nelson PS,. The effects of aging on the molecular and cellular composition of the prostate microenvironment. PLoS ONE 2010; 5 (9): pii:e12501.
30. Penna G, Mondaini N, Amuchastegui S, Degli Innocenti S, Carini M, Giubilei G, Fibbi B, Colli E, Maggi M, Adorini L,. Seminal plasma cytokines and chemokines in prostate inflammation: Interleukin 8 as a predictive biomarker in chronic prostatitis/chronic pelvic pain syndrome and benign prostatic hyperplasia. Eur Urol 2007; 51: 524-533. (Pubitemid 44937795)
31. Penna G, Fibbi B, Amuchastegui S, Cossetti C, Aquilano F, Laverny G, Gacci M, Crescioli C, Maggi M, Adorini L,. Human Benign prostatic hyperplasia stromal cells as inducers and targets of chronic immuno-mediated inflammation. J Immunol 2009; 182: 4056-4064.
32. Zhu J, Yamane H, Paul WE,. Differentiation of effector CD4 T cell populations. Ann Rev Immunol 2010; 28: 445-489.
33. Corona G, Monami M, Rastrelli G, Aversa A, Tishova Y, Saad F, Lenzi A, Forti G, Mannucci E, Maggi M,. Testosterone and metabolic syndrome: A meta-analysis study. J Sex Med 2011; 8: 272-283.
34. Roumeguère T, Zouaoui Boudjeltia K, Babar S, Nuyens V, Rousseau A, Van Antwerpen P, Ducobu J, Wespes E, Vanhaeverbeek M,. Effects of phosphodiesterase inhibitors on the inflammatory response of endothelial cells stimulated by myeloperoxidase-modified low-density lipoprotein or tumor necrosis factor alpha. Eur Urol 2010; 57: 522-528.
35. Armani A, Marzolla V, Rosano GM, Fabbri A, Caprio M,. Phosphodiesterase type 5 (PDE5) in the adipocyte: A novel player in fat metabolism? Trends Endocrinol Metab 2011; 22: 404-411.
36. Handa P, Tateya S, Rizzo NO, Cheng AM, Morgan-Stevenson V, Han CY, Clowes AW, Daum G, O'Brien KD, Schwartz MW, Chait A, Kim F,. Reduced vascular nitric oxide-cGMP signaling contributes to adipose tissue inflammation during high-fat feeding. Arterioscler Thromb Vasc Biol 2011; 31: 2827-2835.